# Pharmaceutical manufacturing: how the industry works Canonical: https://industrywiki.org/industry/pharmaceutical-manufacturing/ Published: 2026-10-26 Pharmaceutical manufacturers convert qualified ingredients and processes into consistent medicine. Product approval, controlled production, testing, and batch release determine what can reach patients. ## scope Covers active pharmaceutical ingredients and finished medicines, including chemical drugs and biologic products. Drug discovery, clinical trials, distribution, and pharmacy dispensing are connected but distinct activities. FDA references explain the U.S. framework, not worldwide requirements. ## segments ### name Active ingredient production ### description Makes the substance responsible for therapeutic activity through chemical synthesis or biological processes; purity and reproducibility are central. ### name Finished dosage forms ### description Formulates ingredients into tablets, capsules, injections, or other forms, with product-specific controls and packaging. ### name Contract development and manufacturing ### description Produces for another company under defined technical and quality agreements. The commercial owner and manufacturing site have different responsibilities. ## flow ### name Develop and validate the process ### description Establish process understanding, qualified inputs, controls, and evidence that the production system consistently delivers required quality. ### name Produce the drug substance ### description Carry out synthesis or biological production, then purification and testing appropriate to the product. ### name Formulate and package ### description Create the dosage form, manage contamination and mix-up risks, and package with the correct identity and labeling. ### name Review and release ### description Review manufacturing records and test results before release. Deviations require investigation rather than automatic acceptance of a finished batch. ## economics ### revenue Unit A qualified batch, unit of active ingredient, or finished dosage unit; contract manufacturers may also charge development and capacity fees. ### payers Marketing authorization holders, distributors, health systems, and other contracted purchasers. The price received by a manufacturer is not necessarily the patient’s out-of-pocket price. ### costs #### name Manufacturing and quality #### explanation Ingredients, specialized equipment, controlled environments, testing, documentation, and quality personnel support each released batch. #### name Development and capacity #### explanation Process development, technology transfer, facility investment, and unused qualified capacity can be material even before routine production. ### capital Facilities are configured for particular processes and product risks. A generic tank or room is not automatically qualified pharmaceutical capacity. ### working Capital Materials and batches can remain unavailable for sale during processing, testing, or investigation. Shelf life limits how far inventory can cushion demand or supply uncertainty. ### mechanism The important output is released, conforming product. Faster production has little value if testing, quality review, or a packaging constraint delays release. Manufacturing cost also should not be confused with the full cost of developing and commercializing a medicine. ## operations ### activities - Material qualification and controlled production - Quality control testing and deviation investigation - Batch review and change control ### assets - Product-specific processing and filling equipment - Qualified laboratories and controlled storage ### roles - Production specialists and process scientists - Quality assurance and quality control personnel ### records - Master and executed batch records - Test results, deviations, and change-control records ### software - Electronic batch and laboratory systems - Quality management and inventory traceability ### metrics #### name Released-batch yield #### definition Released conforming output relative to defined material or batch input. #### why Separates physical throughput from product available for sale. #### name Right-first-time documentation #### definition Records accepted without correction or investigation divided by records reviewed. #### why Documentation defects can delay release even when physical product appears acceptable. #### name Release lead time #### definition Time from batch completion to authorized release. #### why Identifies laboratory, review, and investigation queues. ## structure - Different drug products have different manufacturing constraints. Sterile injectables, chemical tablets, and biologics cannot be understood through a single generic factory model. Product quality depends on process design and control as well as end-product tests. - Technology transfer is an engineering and regulatory exercise. A backup site must reproduce the required process and quality, so adding a supplier is more involved than comparing quotations. Commercial pricing, reimbursement, intellectual property, and manufacturing efficiency are related but separate mechanisms. ## risks ### risk Contamination or mix-up ### mechanism Failures in controls can make an entire batch unsuitable and can require broader investigation or recall. ### risk Single qualified source ### mechanism An ingredient or site interruption can persist because an alternative needs technical qualification and applicable regulatory acceptance. ### risk Data or process-control failure ### mechanism Unreliable records undermine the evidence used to establish quality; satisfactory final testing alone does not replace a compliant process. ## dependencies ### upstream #### slug water-utilities #### label Water utilities #### relationship Provide feedwater which manufacturers treat to the quality required by their processes. #### slug electric-utilities #### label Electric utilities #### relationship Support processing, controlled environments, and storage. ### downstream #### slug healthcare-providers #### label Healthcare providers #### relationship Administer and prescribe medicines as part of care. #### slug wholesale-distribution #### label Wholesale distribution #### relationship Moves released product through qualified distribution channels. ### substitutes #### label Other treatments #### relationship Alternative medicines or non-drug interventions depend on clinical suitability and approval; commercial similarity is not clinical interchangeability. ## worked Example ### title Batch release changes effective output ### assumptions - Illustrative plan: ten batches, each with 100,000 units. - Eight batches are released this month; two remain under investigation. ### calculation - Physical units made: 10 × 100,000 = 1,000,000. - Units available from released batches: 8 × 100,000 = 800,000. ### takeaway The 200,000 held units are not available supply. They are not automatically lost either; their disposition follows the quality investigation. ## scenario ### change A critical supplier changes its production process. ### effects - The medicine manufacturer assesses the change against approved material and process requirements. - Additional evaluation or qualification may be needed before accepting the changed input. - Inventory provides time, but expiry and demand determine how long that buffer lasts. ### watch - Qualified supply coverage - Open material and batch investigations - Release lead time ## misconceptions ### claim Testing the final product is sufficient to guarantee quality. ### correction Quality also depends on controlled methods, facilities, records, and processes; final tests cannot detect every possible failure. ## sources ### id fda-cgmp ### title Current Good Manufacturing Practice (CGMP) Regulations ### organization U.S. Food and Drug Administration ### url https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations ### supports U.S. manufacturing methods, facility controls, and quality requirements. ### id fda-approval ### title How do I go about getting a drug approved? ### organization U.S. Food and Drug Administration ### url https://www.fda.gov/industry/fda-basics-industry/how-do-i-go-about-getting-drug-approved ### supports Relationship between drug development, application review, and manufacturing information. ### id fda-q11 ### title Q11 Development and Manufacture of Drug Substances ### organization U.S. Food and Drug Administration / ICH ### url https://www.fda.gov/files/drugs/published/Q11-Development-and-Manufacture-of-Drug-Substances.pdf ### supports Process development, control strategy, and manufacture of drug substances; 2012 guidance. ## evidence ### scope - fda-approval - fda-q11 ### flow - fda-q11 - fda-cgmp ### economics - fda-q11 - fda-approval ### operations - fda-cgmp - fda-q11 ### structure - fda-q11 ### risks - fda-cgmp ## related Concepts - yield - working-capital - regulation-and-market-entry - switching-costs ## classification ## editorial Note Process descriptions draw on the cited primary sources. Business-model interpretation is editorial synthesis; worked-example figures are illustrative assumptions, not industry benchmarks. Regulation and commercial arrangements vary by jurisdiction. ## companies ### selection Note Illustrative manufacturers spanning innovative medicines, vaccines, generics, active ingredients, and contract manufacturing. This is not a revenue ranking or a recommendation of any medicine; company-level descriptions do not certify individual products or facilities. ### verified On 2026-10-26 ### entries #### name AstraZeneca #### kind Company #### segment Medicines and biologics #### description Manufactures medicines ranging from tablets and inhalers to biologics and injectable therapies. Its operations illustrate how dosage form changes production equipment, quality controls, and supply requirements. #### url https://careers.astrazeneca.com/business-area-operations #### name Dr. Reddy’s Laboratories #### kind Company #### segment Generics and active ingredients #### description Develops and manufactures active pharmaceutical ingredients and supplies generic medicines. Its business illustrates the connection between chemical process capabilities and finished pharmaceutical formulations. #### url https://www.drreddys.com/our-business #### name GSK #### kind Company #### segment Medicines and vaccines #### description Manufactures and supplies medicines and vaccines through its global supply organization. It illustrates coordination among production, technical services, quality assurance, and distribution for regulated products. #### url https://www.gsk.com/en-gb/careers/experienced-professionals/global-supply-chain #### name Lonza #### kind Company #### segment Contract biologics manufacturing #### description Provides development and manufacturing services for biologic medicines. Its contract model illustrates how drug developers obtain production expertise and capacity without owning every manufacturing stage. #### url https://www.lonza.com/integrated-biologics #### name Novartis #### kind Company #### segment Specialized medicine manufacturing #### description Manufactures medicines across small molecules, biologics, cell and gene therapies, and radioligand therapies. Its production network illustrates why different therapeutic technologies require specialized manufacturing capabilities. #### url https://www.novartis.com/about/manufacturing #### name Pfizer #### kind Company #### segment Medicines and vaccines #### description Produces and distributes medicines and vaccines through internal manufacturing sites and external suppliers. Its model illustrates production planning, quality oversight, and supply coordination across a complex portfolio. #### url https://www.pfizer.com/products/how-drugs-are-made/global-supply #### name Roche #### kind Company group #### segment Innovative pharmaceuticals #### description Combines pharmaceutical development with manufacturing and supply capabilities. Its medicines business illustrates the link between research partnerships, production capacity, and bringing regulated therapies to patients. #### url https://www.roche.com/innovation/partnering/pharma #### name Sanofi #### kind Company #### segment Vaccines and pharmaceuticals #### description Manufactures small-molecule medicines, biologics, and vaccines through a global production network. Its operations illustrate the different facilities and process controls required across pharmaceutical technologies. #### url https://www.sanofi.com/en/our-science/manufacturing-and-supply #### name Sun Pharmaceutical Industries #### kind Company #### segment Generics, specialty medicines, and APIs #### description Produces generic and specialty medicines and manufactures active pharmaceutical ingredients for internal use and external customers. It illustrates vertical integration between bulk ingredients and finished products. #### url https://sunpharma.com/products/ #### name Teva Pharmaceutical Industries #### kind Company #### segment Generic and specialty medicines #### description Supplies medicines through a coordinated manufacturing and distribution network. Its business illustrates how production planning and supply reliability support a portfolio spanning generic and innovative treatments. #### url https://www.tevapharm.com/solutions/supply-chain Examples are illustrative, not benchmarks. Editorial method: https://industrywiki.org/methodology/